Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer

Journal of Thoracic and Cardiovascular Surgery

Volumn 135, Issue 5, 2008, Pages 1036-1041

  Kandioler, Daniela ^a   Stamatis, Georgios ^b   Eberhardt, Wilfried ^c   Kappel, Sonja ^a   Zöchbauer Müller, Sabine ^a   Kührer, Irene ^a   Mittlböck, Martina ^a   Zwrtek, Ronald ^d   Aigner, Clemens ^a   Bichler, Christoph ^a   Tichy, Victoria ^a   Hudec, Marcus ^e   Bachleitner, Thomas ^a   End, Adelheid ^a   Müller, Michael Rolf ^a   Roth, Erich ^a   Klepetko, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b RUHRLANDKLINIK   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d Division of Surgery   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA SEQUENCE; FEMALE; GENOTYPE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; GENES, P53; GENOTYPE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOADJUVANT THERAPY; PNEUMONECTOMY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 43049093034     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2007.10.072     Document Type: Article

References (26)

1. Wang G., Reed E., and Li Q.Q. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 12 (2004) 955-965
2. Roth J.A., Fossella F., Komaki R., Ryan M.B., Putnam Jr. J.B., Lee J.S., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 (1994) 673-680
3. Roth J.A., Atkinson E.N., Fossella F., Komaki R., Bernadette Ryan M., Putnam Jr. J.B., et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 21 (1998) 1-6
4. Rosell R., Gomez-Codina J., Camps C., Maestre J., Padille J., Canto A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330 (1994) 153-158
5. Rosell R., Gomez-Codina J., Camps C., Javier Sanchez J., Maestre J., Padilla J., et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 26 (1999) 7-14
6. Dillman R.O., Herndon J., Seagren S.L., Eaton Jr. W.L., and Green M.R. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 88 (1996) 1210-1215
7. Sause W.T., Scott C., Taylor S., Johnson D., Livingston R., Komaki R., et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87 (1995) 198-205
8. Gilligan D., Nicolson M., Smith I., Groen H., Dalesio O., Goldstraw P., et al. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 369 (2007) 1929-1937
9. Pirollo K.F., Bouker K.B., and Chang E.H. Does p53 status influence tumor response to anticancer therapies?. Anticancer Drugs 11 (2000) 419-432
10. Peller S. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. Semin Cancer Biol 8 (1998) 379-387
11. Lowe S.W., Ruley H.E., Jacks T., and Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74 (1993) 957-967
12. Bates S., and Vousden K.H. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55 (1999) 28-37
13. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., et al. p53 status and the efficacy of cancer therapy in vivo. Science 266 (1994) 807-810
14. Lai S.L., Perng R.P., and Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 7 (2000) 64-70
15. Bergqvist M., Brattstrom D., Gullbo J., Hesselius P., Brodin O., and Wagenius G. p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer. Anticancer Res 23 2B (2003) 1207-1212
16. Kandioler-Eckersberger D., Kappel S., Mittlbock M., Dekan G., Ludwig C., Janschek E., et al. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 117 (1999) 744-750
17. Kandioler D. p53 as a prognostic and predictive indicator. In: Gasparini G., and Hayes F. (Eds). Biomarkers in Breast Cancer Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect (2005), Humana Press, Totowa 193-209
18. Shaik M.S., Chatterjee A., Jackson T., and Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer 118 (2006) 396-404
19. Stamatis G., Eberhardt W., Stuben G., Bildat S., Dahler O., and Hillejan L. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg 68 (1999) 1144-1149
20. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
21. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50 (1966) 163-170
22. Klingler A. Statistical methods in surgical research-a practical guide. Eur Surg 36 (2004) 80-84
23. Viktorsson K., De Petris L., and Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 331 (2005) 868-880
24. Steels E., Paesmans M., Berghmans T., Branle F., Lemaitre F., Mascaux C., et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18 (2001) 705-719
25. d'Amato T.A., Landreneau R.J., Ricketts W., Huang W., Parker R., Mechetner E., et al. Chemotherapy resistance and oncogene expression in non-small cell lung cancer. J Thorac Cardiovasc Surg 133 (2007) 352-363
26. vom Brocke J., Schmeiser H.H., Reinbold M., and Hollstein M. MEF immortalization to investigate the ins and outs of mutagenesis. Carcinogenesis 27 (2006) 2141-2147